STOCK TITAN

Neurocrine Biosciences Inc reported $2.9B in revenue and $478.6M in net income for fiscal 2025. See the full NBIX financial statements: income statement, balance sheet, cash flow and ratios, each column linked to its SEC filing.

Neurocrine Biosciences to Present at Upcoming Investor Conferences in September

Neurocrine Biosciences executives will speak at three September 2026 healthcare investor conferences, with live and archived webcasts for investors.

(Neutral)
(Neutral)
Tags
conferences

Neurocrine Biosciences (NBIX)/b) will participate in three investor conferences in September 2026, featuring executive fireside chats at Wells Fargo, Cantor and Morgan Stanley healthcare events.The sessions take place on September 9 in Boston, and September 10 and 15 in New York, with live and replay webcasts available via the company’s investor website.

Loading...
Loading translation...

Positive

  • None.

Negative

  • None.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

SAN DIEGO, Sept. 2, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its executives will participate at the following investor conferences:

  • Wells Fargo 21st Annual Healthcare Conference. Fireside chat on Wednesday, September 9, 2026 at 12:45 PM ET in Boston

  • Cantor Global Healthcare Conference 2026. Fireside chat on Thursday, September 10, 2026 at 8:35 AM ET in New York

  • Morgan Stanley 24th Annual Global Healthcare Conference. Fireside chat on Tuesday, September 15, 2026 at 10:45 AM ET in New York

The webcasts can also be accessed on Neurocrine Biosciences' website under Investors at www.neurocrine.com. A replay of the webcasts will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month.

About Neurocrine Biosciences
Neurocrine Biosciences is a leading biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering, developing and commercializing life-changing treatments for patients with under-addressed neurological, psychiatric, endocrine and immunological disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, hyperphagia in patients with Prader-Willi syndrome, endometriosis* and uterine fibroids,* as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For more than three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedInXFacebook and YouTube. (*in collaboration with AbbVie)  

NEUROCRINE, the NEUROCRINE BIOSCIENCES Logo, and YOU DESERVE BRAVE SCIENCE are registered trademarks of Neurocrine Biosciences, Inc.

Contact: Neurocrine Biosciences, Inc.
Tony Jewell (Media)
858-617-7578
media@neurocrine.com

Todd Tushla (Investors)
858-617-7143
ir@neurocrine.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-to-present-at-upcoming-investor-conferences-in-september-302867834.html

SOURCE Neurocrine Biosciences, Inc.

FAQ

When will Neurocrine Biosciences (NBIX) present at the Wells Fargo 21st Annual Healthcare Conference?

Neurocrine Biosciences will host a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026 at 12:45 PM ET in Boston.

What is the date and time of Neurocrine Biosciences’ Cantor Global Healthcare Conference 2026 presentation?

The company’s executives will participate in a fireside chat at the Cantor Global Healthcare Conference 2026 on Thursday, September 10, 2026 at 8:35 AM ET in New York.

When is Neurocrine Biosciences’ fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference?

Neurocrine Biosciences is scheduled for a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, September 15, 2026 at 10:45 AM ET in New York.

How can investors access the September 2026 Neurocrine Biosciences (NBIX) conference webcasts?

Live webcasts of all three fireside chats can be accessed on Neurocrine Biosciences’ website under the Investors section at www.neurocrine.com. A replay will be available about one hour after each event and archived for approximately one month.